Applying Antisense Technology: Affinitak™ and Other Antisense Oligonucleotides in Clinical Development

Annals of the New York Academy of Sciences

Volumn 1002, Issue , 2003, Pages 244-251

  Holmlund, Jon T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense; ICAM 1; Oligonucleotide; Protein kinase C

Indexed keywords

ALICAFORSEN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CISPLATIN; DOCETAXEL; FOMIVIRSEN; GEMCITABINE; ISIS 104383; ISIS 104838; ISIS 14803; ISIS 23722; ISIS 2503; ISIS 3521; OGX 011; PACLITAXEL; PEGINTERFERON; RIBAVIRIN; SURVIVIN; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CROHN DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HORMONAL THERAPY; HUMAN; INJECTION SITE; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA;

CUCUMBER MOSAIC VIRUS;

EID: 1342332317     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1281.027     Document Type: Conference Paper

References (20)

1. YUPSA, S.H. 1994. The pathogenesis of squamous cell carcinoma: lessons learned from studies of skin carcinogenesis. Cancer Res. 54: 1168.
2. DLUGOSZ, A.J., C. CHENG, E.K. WILLIAMS, et al. 1994. Alterations in murine keratinocyte differentiation induced by activated rasHa genes are mediated by protein kinase C-α. Cancer Res. 54: 6413.
3. WAYS, D.K., C.A. KUKOLY, J. DEVENTE, et al. 1995. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest. 95: 1906.
4. HENTTU, P. & P. VIHKO. 1998. The protein kinase C activator, phorbol ester, elicits disparate functional responses in androgen-sensitive and androgen-independent human prostatic cancer cells. Biochem. Biophys. Res. Commun. 244: 167-171.
5. PERLETTI, G.P., C. SMERALDI, D. PORRO & F. PICCININI. 1994. Involvement of the alpha isoenzyme of protein kinase C in the growth inhibition induced by phorbol esters in MHlCl hepatoma cells. Biochem. Biophys. Res. Commun. 205: 1589-1594.
6. ADESINA, A.M., N. DOOLEY, V.W. YONG & J. NALBANTOGLU. 1998. Differential role for protein kinase C-mediated signaling in the prolifereation of medulloblastoma cell lines. Int J Oncol. 12: 759-768.
7. O'BRIEN, C.A., V.G. VOGEL, S.E. SINGLETARY & N.E. WARD. 1989. Elevated protein kinase C Expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res. 49: 3215.
8. DEAN, N.M. & R. MCKAY. 1994. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphoroothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91: 11762.
9. Affinitak™ Investigator Brochure.
10. YUEN, A.R., J. HALSEY, G.A. FISHER, et al. 1999. Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/ISI 641A) in patients with cancer. Clin. Cancer Res. 5: 3357-3363.
11. NEMUNAITIS, J., J.T. HOLMLUND, M. KRAYNAK, et al. 1999. Phase I evaluation of ISIS 3521 (ISI 641A), an antisense oligodeoxynucleotide to protein kinase C-α, in patients with advanced cancer. J. Clin. Oncol. 17: 3586-3595.
12. YUEN, A.R., J. HALSEY, G.A. FISHER, et al. 2001. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc. ASCO 20: 309a, #1234.
13. ISIS 2503 Investigator Brochure
14. CHEN, G., S. OH, B.P. MONIA & D.W STACEY. 1996. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J. Biol. Chem. 271: 28259-28265.
15. PETIT, T., D.J. BEARSS, D.A. TROYER, et al. 1999. Oligonucleotide targeted against Haras is a ras-transgenic mouse tumor model. Proc. Am. Assoc. Cancer Res. 40: 20.
16. ALBERTS, S.R., M. SCHROEDER, S. CHA, et al. 2002. Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma (ACA): a North Central Cancer Treatment Group (NCCTG) Phase II Study: Interim Analysis. AACR #LB140.
17. ZELLWEGER, T., H. MIYAKE, S. COOPER, et al. 2001. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-0-(2-Methoxy) ethyl chemistry. J. Pharmacol. Exp. Ther. 298: 1-7.
18. YACYSHYN, B.R., M.B. BOWEN-YACYSHYN, L. JEWELL, et al. 1998. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114: 1133.
19. YACYSHYN, B.R., W.Y. CHEY, J. GOFF, et al. 2002. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51: 30-36.
20. SEWELL, K.L., R.S. GEARY, B.F. BAKER, et al. 2002. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α. J. Pharmacol. Exp. Ther. 303: 1334-1343.